Pretreated Refractory HL

In this video, Dr. Filip Janku, from the University of Texas MD Anderson Cancer Center, discusses the findings of a trial that examined the effect of sirolimus and virinostat in patients with Hodgkin lymphoma who

had been heavily pretreated and had refractory disease. Findings from the study were presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting. The combination of the two therapies appeared to be both well tolerated and effective. For more information, click here.

 

Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe

WEIGH-IN WEDNESDAY

Are you aware cancer patients can experience chemo brain without ever receiving chemotherapy?

IN THE NODE

Updates

 

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.